Hepatic C-X-C chemokine receptor type 6-expressing innate lymphocytes limit detrimental myeloid hyperactivation in acute liver injury.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
18
10
2022
accepted:
28
01
2023
medline:
29
3
2023
entrez:
27
3
2023
pubmed:
28
3
2023
Statut:
epublish
Résumé
Acute liver failure (ALF) is characterized by rapid clinical deterioration and high mortality. Acetaminophen (APAP or paracetamol) overdose is a leading cause of ALF, resulting in hepatocellular necrosis with subsequent inflammation, inflicting further liver damage. Infiltrating myeloid cells are early drivers of liver inflammation. However, the role of the abundant population of liver-resident innate lymphocytes, which commonly express the chemokine receptor CXCR6, is incompletely understood in ALF. We investigated the role of CXCR6-expressing innate lymphocytes using the model of acute APAP toxicity in mice deficient in CXCR6 (Cxcr6gfp/gfp). APAP-induced liver injury was strongly aggravated in Cxcr6gfp/gfp mice compared with wild-type counterparts. Immunophenotyping using flow cytometry revealed a reduction in liver CD4+T cells, natural killer (NK) cells, and most prominently, NKT cells, whereas CXCR6 was dispensable for CD8+ T-cell accumulation. CXCR6-deficient mice exhibited excessive neutrophil and inflammatory macrophage infiltration. Intravital microscopy revealed dense cellular clusters of neutrophils in necrotic liver tissue, with higher numbers of clustering neutrophils in Cxcr6gfp/gfp mice. Gene expression analysis linked hyperinflammation in CXCR6 deficiency to increased IL-17 signaling. Although reduced in overall numbers, CXCR6-deficient mice had a shift in NKT cell subsets with increased RORγt-expressing NKT17 cells as a likely source of IL-17. In patients with ALF, we found a prominent accumulation of IL-17-expressing cells. Accordingly, CXCR6-deficient mice lacking IL-17 (Cxcr6gfp/gfpx Il17-/-) had ameliorated liver damage and reduced inflammatory myeloid infiltrates. Our study identifies a crucial role of CXCR6-expressing liver innate lymphocytes as orchestrators in acute liver injury containing IL-17-mediated myeloid cell infiltration. Hence, strengthening the CXCR6-axis or downstream inhibition of IL-17 could yield novel therapeutics in ALF.
Sections du résumé
BACKGROUND
Acute liver failure (ALF) is characterized by rapid clinical deterioration and high mortality. Acetaminophen (APAP or paracetamol) overdose is a leading cause of ALF, resulting in hepatocellular necrosis with subsequent inflammation, inflicting further liver damage. Infiltrating myeloid cells are early drivers of liver inflammation. However, the role of the abundant population of liver-resident innate lymphocytes, which commonly express the chemokine receptor CXCR6, is incompletely understood in ALF.
METHODS
We investigated the role of CXCR6-expressing innate lymphocytes using the model of acute APAP toxicity in mice deficient in CXCR6 (Cxcr6gfp/gfp).
RESULTS
APAP-induced liver injury was strongly aggravated in Cxcr6gfp/gfp mice compared with wild-type counterparts. Immunophenotyping using flow cytometry revealed a reduction in liver CD4+T cells, natural killer (NK) cells, and most prominently, NKT cells, whereas CXCR6 was dispensable for CD8+ T-cell accumulation. CXCR6-deficient mice exhibited excessive neutrophil and inflammatory macrophage infiltration. Intravital microscopy revealed dense cellular clusters of neutrophils in necrotic liver tissue, with higher numbers of clustering neutrophils in Cxcr6gfp/gfp mice. Gene expression analysis linked hyperinflammation in CXCR6 deficiency to increased IL-17 signaling. Although reduced in overall numbers, CXCR6-deficient mice had a shift in NKT cell subsets with increased RORγt-expressing NKT17 cells as a likely source of IL-17. In patients with ALF, we found a prominent accumulation of IL-17-expressing cells. Accordingly, CXCR6-deficient mice lacking IL-17 (Cxcr6gfp/gfpx Il17-/-) had ameliorated liver damage and reduced inflammatory myeloid infiltrates.
CONCLUSIONS
Our study identifies a crucial role of CXCR6-expressing liver innate lymphocytes as orchestrators in acute liver injury containing IL-17-mediated myeloid cell infiltration. Hence, strengthening the CXCR6-axis or downstream inhibition of IL-17 could yield novel therapeutics in ALF.
Identifiants
pubmed: 36972392
doi: 10.1097/HC9.0000000000000102
pii: 02009842-202304010-00024
pmc: PMC10503691
pii:
doi:
Substances chimiques
Acetaminophen
362O9ITL9D
Interleukin-17
0
Cxcr6 protein, mouse
0
Receptors, CXCR6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Hepatology. 2012 Mar;55(3):898-909
pubmed: 22031018
Mediators Inflamm. 2015;2015:368427
pubmed: 26494947
Cancer Cell. 2014 Oct 13;26(4):549-64
pubmed: 25314080
Immune Netw. 2018 Aug 13;18(4):e27
pubmed: 30181915
Gastroenterology. 2019 May;156(6):1877-1889.e4
pubmed: 30710528
Gastroenterology. 2012 Nov;143(5):1158-1172
pubmed: 22982943
Lancet. 2010 Jul 17;376(9736):190-201
pubmed: 20638564
J Immunol. 2008 Jul 1;181(1):81-91
pubmed: 18566372
Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):391-402
pubmed: 30476545
Curr Opin Immunol. 2013 Apr;25(2):161-7
pubmed: 23402834
Hepatology. 2016 Nov;64(5):1667-1682
pubmed: 27302828
J Immunol. 2000 Sep 15;165(6):3284-92
pubmed: 10975845
Nature. 2021 Apr;592(7854):444-449
pubmed: 33762736
J Hepatol. 2022 Oct;77(4):1136-1160
pubmed: 35750137
N Engl J Med. 2013 Dec 26;369(26):2525-34
pubmed: 24369077
Liver Int. 2012 Jan;32(1):8-20
pubmed: 21745276
Cell Mol Immunol. 2021 Jan;18(1):57-72
pubmed: 33041339
PLoS Biol. 2005 Apr;3(4):e113
pubmed: 15799695
Hepatology. 2013 Jan;57(1):373-84
pubmed: 22821628
Hepatobiliary Surg Nutr. 2014 Dec;3(6):331-43
pubmed: 25568858
Biochem Biophys Res Commun. 2012 Nov 16;428(2):245-51
pubmed: 23079619
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
J Immunol. 2013 May 15;190(10):5226-36
pubmed: 23596313
Sci Rep. 2016 May 23;6:26157
pubmed: 27210614
J Exp Med. 2018 Dec 3;215(12):3006-3018
pubmed: 30455268
Immunity. 2017 Oct 17;47(4):752-765.e5
pubmed: 29045904
J Leukoc Biol. 2009 Sep;86(3):513-28
pubmed: 19542050
Nat Rev Immunol. 2010 Jul;10(7):479-89
pubmed: 20559326
Gastroenterology. 2014 Sep;147(3):577-594.e1
pubmed: 25066692
J Immunol. 2010 Apr 15;184(8):4531-7
pubmed: 20228195
Methods. 2017 Sep 1;128:12-19
pubmed: 28522327
Adv Pharmacol. 2019;85:195-219
pubmed: 31307587
J Immunol. 2016 Sep 15;197(6):2400-8
pubmed: 27534549
Hepatology. 2013 Apr;57(4):1575-84
pubmed: 23150232
Toxicol Lett. 2018 Aug;292:20-30
pubmed: 29689376
Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88-110
pubmed: 26758786
J Immunol. 2006 Nov 15;177(10):6650-9
pubmed: 17082577